Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Solid Biosciences Inc (NASDAQ: SLDB) was $5.9 for the day, up 2.79% from the previous closing price of $5.74. In other words, the price has increased by $2.79 from its previous closing price. On the day, 1.19 million shares were traded. SLDB stock price reached its highest trading level at $6.005 during the session, while it also had its lowest trading level at $5.75.
Ratios:
Our analysis of SLDB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 9.34 and its Current Ratio is at 9.34. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Citigroup on June 26, 2025, initiated with a Buy rating and assigned the stock a target price of $14.
On January 08, 2025, Truist started tracking the stock assigning a Buy rating and target price of $16.
On December 13, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $16.Wedbush initiated its Outperform rating on December 13, 2024, with a $16 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 11 ’25 when Kahn Clare bought 1,860 shares for $5.34 per share. The transaction valued at 9,924 led to the insider holds 2,960 shares of the business.
Bain Capital Life Sciences Inv bought 1,000,000 shares of SLDB for $4,030,000 on Feb 19 ’25. The 10% Owner now owns 5,034,582 shares after completing the transaction at $4.03 per share. On Feb 19 ’25, another insider, PERCEPTIVE ADVISORS LLC, who serves as the Director of the company, bought 5,000,000 shares for $4.03 each. As a result, the insider paid 20,150,000 and bolstered with 11,833,539 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLDB now has a Market Capitalization of 459427520 and an Enterprise Value of 214368512.
Stock Price History:
The Beta on a monthly basis for SLDB is 2.77, which has changed by -0.10470408 over the last 52 weeks, in comparison to a change of 0.17904854 over the same period for the S&P500. Over the past 52 weeks, SLDB has reached a high of $7.37, while it has fallen to a 52-week low of $2.41. The 50-Day Moving Average of the stock is -0.42%, while the 200-Day Moving Average is calculated to be 29.10%.
Shares Statistics:
SLDB traded an average of 1.19M shares per day over the past three months and 1350200 shares per day over the past ten days. A total of 77.60M shares are outstanding, with a floating share count of 58.34M. Insiders hold about 25.08% of the company’s shares, while institutions hold 83.80% stake in the company. Shares short for SLDB as of 1757894400 were 9941427 with a Short Ratio of 8.33, compared to 1755216000 on 9780877. Therefore, it implies a Short% of Shares Outstanding of 9941427 and a Short% of Float of 15.17.
Earnings Estimates
The stock of Solid Biosciences Inc (SLDB) is currently drawing attention from 11.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.4 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$1.75 and -$2.8 for the fiscal current year, implying an average EPS of -$2.03. EPS for the following year is -$1.98, with 10.0 analysts recommending between -$1.34 and -$2.68.
